Topic:

Biologics

Latest Headlines

Latest Headlines

AstraZeneca says Sweden getting its new $285M biologics plant

Having laid out plans last fall to expand a biologics plant in the U.S., AstraZeneca is now planning to build a new large-molecule filling facility in Sweden, adding up to 250 jobs in the process. The U.K. drugmaker says the new facility is part of a bigger plan for its biologics manufacturing, the details of which it will announce later.

Danaher, drawn by Pall's biopharma biz, will pay $13.8B for filtration specialist

Drugmakers are developing more biologic drugs and building new plants to manufacture them. And given that those plants all need filtration systems, analysts say it is no wonder that Pall would become a buyout prize. The Port Washington, NY-based company is being scooped up in $13.8 billion deal that rivals those orchestrated by some of its pharma clients.

UPDATED: Merck injects another $12.4M in its newest vaccine plant

The $335 million Merck & Co. biologics plant in Ireland that went online last year is already getting another investment. Merck said last week that it would invest €11.5 million ($12.4 million) in the Carlow facility.

Roche's Genentech investing $125M in Oregon plant

With a bunch of biologic drugs in development, Roche's Genentech sees the need for more production capacity. To meet it, the biotech is expanding a fill/finish facility in Oregon, investing more than $100 million on the project and adding dozens of jobs there.

Merck bets big on NGM with a $450M handshake

Taking a page from famed partners like Sanofi and Regeneron and Roche and Genentech, Merck has signed a sweeping R&D deal with biotech NGM Biopharmaceuticals, promising up to $450 million for 5 years of pipeline-building collaboration.

China's Innovent banks $100M to cash in on the biosimilar boom

Innovent Biologics has raised $100 million in venture cash in hopes of becoming the premier maker of biotech drugs in its native China, advancing a pipeline of biosimilars and proprietary treatments.

CPhI: Biocon will add 'multifold capacity' as it powers into biosimilars

Kiran Mazumdar-Shaw, founder and managing director of India's Biocon, has had an interesting 36-year journey from brew master to biosimilars maker. She says her vision has always been for Biocon to affect global health in a big way.

Serum Institute allies with biotech in bid to cut cost of biosimilar production

The biosimilars market has attracted some big companies with even bigger claims about their ability to drive down manufacturing costs, with Samsung and its ambition to undercut biologic prices by 50% the standout example. Now a small Australian biotech is trumpeting the cost-saving it can realize after marrying its expression technology to the scale of the Serum Institute of India.

Bristol-Myers extends manufacturing pact with Samsung

Bristol-Myers Squibb hooked up with South Korea's Samsung last year when it wanted someone to handle manufacturing overseas for its hot-selling melanoma drug Yervoy. But with more promising biologics in its pipeline, the New York-based drugmaker has decided to deepen its commitment.

U.K. starts work on $64M biologics manufacturing center

The U.K. is investing £38 million in its National Biologics Manufacturing Centre, part of the country's "High Value Manufacturing Catapult" effort started several years ago to increase its presence in biologics.